Aspirin failure in patients presenting with acute cerebrovascular ischaemia

Saeed H. M. Halawani, David J. P. Williams, John Webster, Michael Greaves, Isobel Ford (Corresponding Author)

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Aspirin is the most commonly used antiplatelet drug for prevention of ischaemic stroke. In order to determine the prevalence and nature of aspirin failure, we studied 51 adults admitted with suspected ischaemic stroke and already prescribed daily aspirin. Within 48 hours (h) of onset, blood and urine samples were collected to assess platelet aggregation, activation and aspirin response by a range of methods. All tests were then repeated on a second sample taken 24 h after witnessed administration of 75 mg or 150 mg aspirin. At entry to the study, incomplete response to aspirin, measured by arachidonic acid (AA)-stimulated platelet aggregation, was found in 43% of patients. Following in-hospital aspirin administration, there was a significant decrease in AA-aggregation (p=0.001) suggesting poor adherence to therapy prior to admission. However, residual aggregation (10–15%) persisted in 11 subjects – suggesting alternative causes. In incomplete responders on admission, platelet aggregation with adenosine diphosphate (ADP) was significantly higher compared with responders (p<0.05) but there were no significant differences in collagen aggregation, platelet fibrinogen binding or P-selectin expression, plasma von Willebrand factor, fibrinogen, high-sensitivity C-reactive protein, or the urinary metabolite, 11-dehydro-TxB2. Incomplete platelet inhibition is common around the time of acute cerebrovascular ischaemic events in patients prescribed aspirin. Up to 50% of these observations appear due to incomplete adherence to aspirin therapy. Intervention studies are required to determine the clinical relevance of measured platelet response to aspirin in terms of outcome, and the effectiveness of improved pharmacotherapy for stroke prevention.
Original languageEnglish
Pages (from-to)240-247
Number of pages8
JournalThrombosis and Haemostasis
Volume106
Issue number2
Early online date5 May 2011
DOIs
Publication statusPublished - Aug 2011

Fingerprint

Aspirin
Ischemia
Platelet Aggregation
Stroke
Arachidonic Acid
Fibrinogen
Blood Platelets
Hospital Administration
P-Selectin
Platelet Aggregation Inhibitors
Platelet Activation
von Willebrand Factor
C-Reactive Protein
Adenosine Diphosphate
Collagen
Urine
Drug Therapy
Therapeutics

Keywords

  • aspirin
  • stroke
  • TIA
  • platelets
  • pharmacotherapy

Cite this

Halawani, S. H. M., Williams, D. J. P., Webster, J., Greaves, M., & Ford, I. (2011). Aspirin failure in patients presenting with acute cerebrovascular ischaemia. Thrombosis and Haemostasis, 106(2), 240-247. https://doi.org/10.1160/TH11-01-0045

Aspirin failure in patients presenting with acute cerebrovascular ischaemia. / Halawani, Saeed H. M.; Williams, David J. P.; Webster, John; Greaves, Michael; Ford, Isobel (Corresponding Author).

In: Thrombosis and Haemostasis, Vol. 106, No. 2, 08.2011, p. 240-247.

Research output: Contribution to journalArticle

Halawani, SHM, Williams, DJP, Webster, J, Greaves, M & Ford, I 2011, 'Aspirin failure in patients presenting with acute cerebrovascular ischaemia', Thrombosis and Haemostasis, vol. 106, no. 2, pp. 240-247. https://doi.org/10.1160/TH11-01-0045
Halawani, Saeed H. M. ; Williams, David J. P. ; Webster, John ; Greaves, Michael ; Ford, Isobel. / Aspirin failure in patients presenting with acute cerebrovascular ischaemia. In: Thrombosis and Haemostasis. 2011 ; Vol. 106, No. 2. pp. 240-247.
@article{c1bb6994535048789142298f3969dd7e,
title = "Aspirin failure in patients presenting with acute cerebrovascular ischaemia",
abstract = "Aspirin is the most commonly used antiplatelet drug for prevention of ischaemic stroke. In order to determine the prevalence and nature of aspirin failure, we studied 51 adults admitted with suspected ischaemic stroke and already prescribed daily aspirin. Within 48 hours (h) of onset, blood and urine samples were collected to assess platelet aggregation, activation and aspirin response by a range of methods. All tests were then repeated on a second sample taken 24 h after witnessed administration of 75 mg or 150 mg aspirin. At entry to the study, incomplete response to aspirin, measured by arachidonic acid (AA)-stimulated platelet aggregation, was found in 43{\%} of patients. Following in-hospital aspirin administration, there was a significant decrease in AA-aggregation (p=0.001) suggesting poor adherence to therapy prior to admission. However, residual aggregation (10–15{\%}) persisted in 11 subjects – suggesting alternative causes. In incomplete responders on admission, platelet aggregation with adenosine diphosphate (ADP) was significantly higher compared with responders (p<0.05) but there were no significant differences in collagen aggregation, platelet fibrinogen binding or P-selectin expression, plasma von Willebrand factor, fibrinogen, high-sensitivity C-reactive protein, or the urinary metabolite, 11-dehydro-TxB2. Incomplete platelet inhibition is common around the time of acute cerebrovascular ischaemic events in patients prescribed aspirin. Up to 50{\%} of these observations appear due to incomplete adherence to aspirin therapy. Intervention studies are required to determine the clinical relevance of measured platelet response to aspirin in terms of outcome, and the effectiveness of improved pharmacotherapy for stroke prevention.",
keywords = "aspirin, stroke , TIA , platelets , pharmacotherapy",
author = "Halawani, {Saeed H. M.} and Williams, {David J. P.} and John Webster and Michael Greaves and Isobel Ford",
year = "2011",
month = "8",
doi = "10.1160/TH11-01-0045",
language = "English",
volume = "106",
pages = "240--247",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "2",

}

TY - JOUR

T1 - Aspirin failure in patients presenting with acute cerebrovascular ischaemia

AU - Halawani, Saeed H. M.

AU - Williams, David J. P.

AU - Webster, John

AU - Greaves, Michael

AU - Ford, Isobel

PY - 2011/8

Y1 - 2011/8

N2 - Aspirin is the most commonly used antiplatelet drug for prevention of ischaemic stroke. In order to determine the prevalence and nature of aspirin failure, we studied 51 adults admitted with suspected ischaemic stroke and already prescribed daily aspirin. Within 48 hours (h) of onset, blood and urine samples were collected to assess platelet aggregation, activation and aspirin response by a range of methods. All tests were then repeated on a second sample taken 24 h after witnessed administration of 75 mg or 150 mg aspirin. At entry to the study, incomplete response to aspirin, measured by arachidonic acid (AA)-stimulated platelet aggregation, was found in 43% of patients. Following in-hospital aspirin administration, there was a significant decrease in AA-aggregation (p=0.001) suggesting poor adherence to therapy prior to admission. However, residual aggregation (10–15%) persisted in 11 subjects – suggesting alternative causes. In incomplete responders on admission, platelet aggregation with adenosine diphosphate (ADP) was significantly higher compared with responders (p<0.05) but there were no significant differences in collagen aggregation, platelet fibrinogen binding or P-selectin expression, plasma von Willebrand factor, fibrinogen, high-sensitivity C-reactive protein, or the urinary metabolite, 11-dehydro-TxB2. Incomplete platelet inhibition is common around the time of acute cerebrovascular ischaemic events in patients prescribed aspirin. Up to 50% of these observations appear due to incomplete adherence to aspirin therapy. Intervention studies are required to determine the clinical relevance of measured platelet response to aspirin in terms of outcome, and the effectiveness of improved pharmacotherapy for stroke prevention.

AB - Aspirin is the most commonly used antiplatelet drug for prevention of ischaemic stroke. In order to determine the prevalence and nature of aspirin failure, we studied 51 adults admitted with suspected ischaemic stroke and already prescribed daily aspirin. Within 48 hours (h) of onset, blood and urine samples were collected to assess platelet aggregation, activation and aspirin response by a range of methods. All tests were then repeated on a second sample taken 24 h after witnessed administration of 75 mg or 150 mg aspirin. At entry to the study, incomplete response to aspirin, measured by arachidonic acid (AA)-stimulated platelet aggregation, was found in 43% of patients. Following in-hospital aspirin administration, there was a significant decrease in AA-aggregation (p=0.001) suggesting poor adherence to therapy prior to admission. However, residual aggregation (10–15%) persisted in 11 subjects – suggesting alternative causes. In incomplete responders on admission, platelet aggregation with adenosine diphosphate (ADP) was significantly higher compared with responders (p<0.05) but there were no significant differences in collagen aggregation, platelet fibrinogen binding or P-selectin expression, plasma von Willebrand factor, fibrinogen, high-sensitivity C-reactive protein, or the urinary metabolite, 11-dehydro-TxB2. Incomplete platelet inhibition is common around the time of acute cerebrovascular ischaemic events in patients prescribed aspirin. Up to 50% of these observations appear due to incomplete adherence to aspirin therapy. Intervention studies are required to determine the clinical relevance of measured platelet response to aspirin in terms of outcome, and the effectiveness of improved pharmacotherapy for stroke prevention.

KW - aspirin

KW - stroke

KW - TIA

KW - platelets

KW - pharmacotherapy

U2 - 10.1160/TH11-01-0045

DO - 10.1160/TH11-01-0045

M3 - Article

VL - 106

SP - 240

EP - 247

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 2

ER -